While Aquestive Therapeutics Inc has underperformed by -1.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST rose by 238.46%, with highs and lows ranging from $6.23 to $1.35, whereas the simple moving average jumped by 35.45% in the last 200 days.
On May 10, 2024, Leerink Partners started tracking Aquestive Therapeutics Inc (NASDAQ: AQST) recommending Outperform. A report published by Piper Sandler on April 11, 2024, Initiated its previous ‘Overweight’ rating for AQST. Raymond James also rated AQST shares as ‘Outperform’, setting a target price of $7 on the company’s shares in an initiating report dated March 28, 2024. RBC Capital Mkts Initiated an Outperform rating on April 07, 2021, and assigned a price target of $7. H.C. Wainwright initiated its ‘Buy’ rating for AQST, as published in its report on April 22, 2019. Lake Street’s report from January 03, 2019 suggests a price prediction of $14 for AQST shares, giving the stock a ‘Buy’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of Aquestive Therapeutics Inc (AQST)
Further, the quarter-over-quarter increase in sales is 51.79%, showing a positive trend in the upcoming months.
One of the most important indicators of Aquestive Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 6.98, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and AQST is recording 1.31M average volume. On a monthly basis, the volatility of the stock is set at 5.90%, whereas on a weekly basis, it is put at 5.06%, with a loss of -0.21% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.44, showing growth from the present price of $4.84, which can serve as yet another indication of whether AQST is worth investing in or should be passed over.
How Do You Analyze Aquestive Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.84%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 39.58% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AQST shares are owned by institutional investors to the tune of 39.58% at present.
